Skip to main content
European Commission logo print header

Polymer-virus hybrid vectors for safe and efficient gene therapy of prostate cancer

Objectif

Efficient and safe vectors for gene therapy of prostate and bladder cancer will be developed by modification of viruses with multivalent hydrophilic polymers. This approach is particularly powerful because it permits complete shielding of viral tropism without genetic engineering. The resulting vectors are less immunogenicthan normal viruses and will be targeted to tumour cell-surface receptors. Their infectivity of these vectors is not affected by neutralising antibodies in serum, a major limitation of current use of viruses for gene delivery - particularly in the clinics. Viruses retargeted in this way operate at a lower MOI than regular viruses in serum and maintain extremely high efficiency of gene expression. These vectors should provide an effective means to realise the substantial promise of gene therapy, and this proposal combines cell/molecular biology and virology with polymer chemistry in their development.

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Contribution de l’UE
Aucune donnée
Adresse
Woodstock Road
OX2 6he OXFORD
Royaume-Uni

Voir sur la carte

Coût total
Aucune donnée

Participants (2)